A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 665
- Population
- ALL · 18 Years to 80 Years
- Duration
- 2008-06-01 to 2010-06-01
- Intervention
- liraglutide; sitagliptin; metformin
- Comparator
- Sita -> Sita
- Outcomes measured
- Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26 — Week 0, Week 26; Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 — Week 0, Week 52; Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 78 — Week 0, Week 78; Mean Change in Glycosylated Haemoglobin A1c (HbA1c) From Week 52 to Week 78 — Week 52, Week 78; Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 26 — Week 0, Week 26; Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 52 — Week 0, Week 52; Percentage of Subjects Achieving Treatment Target of HbA1c < 7.0% at Week 78 — Week 0, Week 78; Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 26 — Week 0, Week 26; Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 52 — Week 0, Week 52; Percentage of Subjects Achieving Treatment Target of HbA1c =< 6.5% at Week 78 — Week 0, Week 78; Mean Change From Baseline in Body Weight at Week 26 — Week 0, Week 26; Mean Change From Baseline in Body Weight at Week 52 — Week 0, Week 52; Mean Change in Body Weight From Week 52 to Week 78 — Week 52, Week 78; Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 — Week 0, Week 26; Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52 — Week 0, Week 52; Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 78 — Week 0, Week 78; Mean Change in Fasting Plasma Glucose (FPG) From Week 52 to Week 78 — Week 52, Week 78; Mean Change From Baseline in Beta-cell Function at Week 26 — Week 0, Week 26; Mean Change From Baseline in Beta-cell Function at Week 52 — Week 0, Week 52; Mean Change in Beta-cell Function From Week 52 to Week 78 — Week 52, Week 78
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Metformin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.